THE DEAL, AT A GLANCE
From the announcementWaypoint Bio
01What it doesWaypoint Bio is a Digital Health company focused on Advance AI-Designed Cell Therapies Toward the Clinic.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Amplify PartnersFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedWaypoint Bio raised $20M Series A, announced 2026-06-01From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersWaypoint Bio's $20M Series A positions the company as a smaller Healthcare & Life Sciences financing in an active sector, with the round at the 21th percentile despite…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Waypoint Bio · Financing Record
Explore source-linked visual explanations for Waypoint Bio. Unsupported claims are withheld while source review continues.
Record 5063 · Recorded date: 2026-06-01
Explore company records →